Meribank Competitors

Stocks . Taiwan . 
Stock . Meribank Biotech Co
4724 Stock   15.45  0.05  0.32%   
Meribank Biotech competes with Chunghwa Chemical, Enimmune Corporation, Genomics BioSci, GenMont Biotech, and GeneReach Biotechnology; as well as few others. Analyzing Meribank Biotech competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Meribank Biotech to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

Meribank Biotech vs Abnova Taiwan Correlation

Very good diversification

The correlation between Meribank Biotech Co and 4133 is -0.4 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Meribank Biotech Co and 4133 in the same portfolio, assuming nothing else is changed.

Moving against Meribank Stock

  0.552412 Chunghwa TelecomPairCorr
  0.332317 Hon Hai PrecisionPairCorr

Meribank Biotech Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Meribank Biotech and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Meribank and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Meribank Biotech does not affect the price movement of the other competitor.

High positive correlations

4133
+ 0.78
1762
4171
+ 0.71
6709
3164
+ 0.69
6709
4133
+ 0.6
4171
4133
+ 0.58
6676
6676
+ 0.49
7427
  

High negative correlations

6564
- 0.09
6872
3164
- 0.07
6564

Risk-Adjusted Indicators

There is a big difference between Meribank Stock performing well and Meribank Biotech Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Meribank Biotech's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
6872  0.96 (0.03)(0.07)(0.03) 1.05 
(1.22)
 2.32 
(1.91)
 6.77 
1762  0.58 (0.04) 0.00 (0.12) 0.00 
 0.00 
 1.41 
(1.16)
 4.75 
6709  1.69 (0.35) 0.00 (0.87) 0.00 
 0.00 
 3.20 
(3.71)
 16.90 
6564  1.40  0.10  0.02 (0.91) 1.34 
(1.88)
 4.78 
(2.33)
 9.31 
4195  1.39 (0.16) 0.00 (5.60) 0.00 
 0.00 
 3.80 
(3.21)
 8.92 
3164  0.53 (0.07) 0.00 (0.19) 0.00 
 0.00 
 1.09 
(1.32)
 3.31 
7427  4.83  0.81  0.10 (0.92) 6.04 
(6.69)
 25.82 
(5.16)
 76.20 
4171  2.77  0.34  0.11  0.54  2.64 
(3.77)
 9.89 
(5.17)
 19.35 
6676  2.14  0.30  0.10  1.61  2.05 
(2.94)
 5.26 
(4.47)
 22.10 
4133  0.76 (0.10) 0.00 (1.87) 0.00 
 0.00 
 1.19 
(1.67)
 5.77 

Meribank Biotech Competitive Analysis

The better you understand Meribank Biotech competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Meribank Biotech's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Meribank Biotech's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
4724 6872 1762 6709 6564 4195 3164 7427 4171 6676
 0.32 
 15.45 
Meribank
 0.25 
 20.25 
NaviFUS
 0.19 
 25.85 
Chunghwa
 7.18 
 28.35 
Advagene
 0.48 
 20.75 
Enimmune
 1.02 
 24.80 
Genomics
 1.93 
 18.45 
GenMont
 5.16 
 38.60 
Great
 2.08 
 21.15 
GeneReach
 2.24 
 15.30 
Sunny
Market Volatility
(90 Days Market Risk)
Not too volatile
Very steady
Very steady
Very steady
Not too volatile
Very steady
Very steady
Somewhat reliable
Not too volatile
Not too volatile
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Weakest
Soft
Weakest
Weakest
Mild
Weakest
Fair
Odds of Financial Distress
(Probability Of Bankruptcy)
Unknown
Unknown
Low
Fair
High
Low
Low
Unknown
Low
Unknown
Current Valuation
(Equity Enterprise Value)
Over Valued
Fairly Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Fairly Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Cautious Hold
Cautious Hold
Cautious Hold
Strong Sell
Strong Sell
Hold
Strong Sell
Hold
Cautious Hold
Current Ratio
N/A
N/A
1.36
N/A
15.1
3.01
12.73
N/A
5.21
N/A
Net Asset
N/A
N/A
4.38 B
N/A
N/A
N/A
1.7 B
N/A
1.68 B
N/A
Profit Margin
N/A
N/A
0.23
N/A
-81.58
N/A
0.23
N/A
0.38
N/A
EBITDA
N/A
N/A
632.93 M
N/A
(66.03 M)
25.55 M
161.32 M
N/A
535.64 M
N/A
Operating Margin
N/A
N/A
0.22
N/A
-101.32
N/A
0.2
N/A
0.43
N/A
Current Valuation
N/A
N/A
5.19 B
N/A
1.94 B
N/A
1.76 B
N/A
2.09 B
N/A
Price To Book
N/A
N/A
1.56
N/A
3.96
N/A
1.58
N/A
2.37
N/A
Retained Earnings
N/A
N/A
630 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Asset
N/A
N/A
729 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Five Year Return
N/A
N/A
2.83
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
N/A
N/A
0.86
N/A
0.37
0.64
0.34
N/A
0.63
N/A
Number Of Employees
N/A
N/A
21
10
27
16
13
N/A
16
N/A
Shares Outstanding
N/A
N/A
77.56 M
N/A
60 M
N/A
86.37 M
N/A
45.97 M
N/A
Cash Flow From Operations
N/A
N/A
219.18 M
N/A
(114.54 M)
40.87 M
111.66 M
N/A
348.99 M
N/A
Annual Yield
N/A
N/A
0.0198
N/A
N/A
N/A
0.0465
N/A
0.0835
N/A
Total Debt
N/A
N/A
600 M
N/A
7.97 M
86.52 M
34.08 M
N/A
217.39 M
N/A
Return On Equity
N/A
N/A
0.17
N/A
-9.41
N/A
0.0535
N/A
0.3
N/A
Z Score
N/A
N/A
4.8
N/A
N/A
9.0
36.0
N/A
7.2
N/A
Return On Asset
N/A
N/A
0.066
N/A
-6.93
N/A
0.0289
N/A
0.13
N/A
Book Value Per Share
N/A
N/A
39.98
N/A
10.29
12.89
15.62
N/A
24.36
N/A
Current Liabilities
N/A
N/A
617 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Asset
N/A
N/A
4.38 B
N/A
N/A
N/A
1.7 B
N/A
1.68 B
N/A
Debt To Equity
N/A
N/A
41.0
N/A
0.013
0.11
2.1
N/A
0.3
N/A
Target Price
N/A
N/A
125.0
N/A
N/A
N/A
102.0
N/A
N/A
N/A
Last Dividend Paid
N/A
N/A
1.3
N/A
N/A
1.17
1.1
N/A
4.55
N/A
Shares Owned By Institutions
N/A
N/A
4.61
N/A
N/A
N/A
0.42
N/A
4.57
N/A
Market Capitalization
N/A
N/A
5.17 B
879.46 M
2.44 B
1.34 B
2.05 B
N/A
2.73 B
N/A
Price To Earning
N/A
N/A
9.2
N/A
N/A
26.25
12.36
N/A
8.39
N/A
Price To Sales
N/A
N/A
2.37
N/A
33.44
N/A
5.47
N/A
2.88
N/A
Net Income
N/A
N/A
400.78 M
N/A
(59.64 M)
45.34 M
113.13 M
N/A
376.62 M
N/A
Earnings Per Share
N/A
N/A
6.21
N/A
-1.4
0.72
1.01
N/A
6.9
N/A
Shares Owned By Insiders
N/A
N/A
39.75
N/A
N/A
N/A
37.09
N/A
34.96
N/A
Revenue
N/A
N/A
1.93 B
N/A
73.11 M
N/A
427.93 M
N/A
1.01 B
N/A
Working Capital
N/A
N/A
112 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
N/A
N/A
97.43 M
N/A
390.32 M
110.98 M
999.04 M
N/A
811.4 M
N/A
Cash Per Share
N/A
N/A
1.26
N/A
6.51
1.76
11.24
N/A
17.65
N/A
Gross Profit
N/A
N/A
949.39 M
N/A
8.22 M
N/A
299.33 M
N/A
746.98 M
N/A
Day Typical Price
15.25
20.22
25.8
28.33
20.7
24.67
18.08
39.23
21.08
15.58
Accumulation Distribution
0.0388
0.0196
0.0173
0.0123
0.0263
0.032
0.0596
0.0636
0.0327
0.0586
Market Facilitation Index
0.6
0.4
0.45
0.35
0.55
0.8
1.1
2.6
0.7
0.95
Daily Balance Of Power
(0.08)
0.125
(0.11)
5.428571
(0.18)
0.3125
0.3182
(0.81)
(0.64)
(0.37)
Period Momentum Indicator
(0.05)
0.05
(0.05)
1.9
(0.10)
0.25
0.35
(2.10)
(0.45)
(0.35)
Rate Of Daily Change
1.0
1.0
1.0
1.07
1.0
1.01
1.02
0.95
0.98
0.98
Day Median Price
15.15
20.2
25.78
28.33
20.67
24.6
17.9
39.55
21.05
15.73
Price Action Indicator
0.27
0.075
0.05
0.98
0.025
0.33
0.72
(2.00)
(0.13)
(0.60)
Coefficient Of Variation
(7,369)
92619.34
(4,945)
(831.64)
1915.68
(1,327)
(1,676)
1357.73
1029.22
1111.58
Mean Deviation
1.35
0.9631
0.5842
1.69
1.4
1.39
0.5281
4.83
2.77
2.14
Jensen Alpha
(0.05)
(0.03)
(0.04)
(0.35)
0.0989
(0.16)
(0.07)
0.8128
0.3398
0.301
Total Risk Alpha
(0.26)
(0.13)
(0.11)
(0.57)
(0.09)
(0.34)
(0.12)
(0.22)
0.0056
(0.02)
Sortino Ratio
N/A
(0.07)
N/A
N/A
0.0164
N/A
N/A
0.0959
0.1108
0.0955
Downside Variance
N/A
1.25
N/A
N/A
2.09
N/A
N/A
51.46
8.38
6.63
Standard Deviation
2.37
1.35
0.8602
2.63
1.95
1.96
0.7255
10.41
4.11
3.61
Kurtosis
7.92
2.74
4.18
8.38
3.89
1.42
1.22
11.14
1.34
13.24
Potential Upside
5.26
2.32
1.41
3.2
4.78
3.8
1.09
25.82
9.89
5.26
Treynor Ratio
(0.27)
(0.03)
(0.12)
(0.87)
(0.91)
(5.60)
(0.19)
(0.92)
0.541
1.61
Maximum Drawdown
14.75
6.77
4.75
16.9
9.31
8.92
3.31
76.2
19.35
22.1
Variance
5.64
1.83
0.7399
6.93
3.82
3.85
0.5264
108.31
16.86
13.0
Market Risk Adjusted Performance
(0.26)
(0.02)
(0.11)
(0.86)
(0.90)
(5.59)
(0.18)
(0.91)
0.551
1.62
Risk Adjusted Performance
(0)
0.0054
(0.01)
(0.08)
0.0445
(0.05)
(0.04)
0.0632
0.0794
0.0738
Skewness
1.97
1.19
1.34
1.89
1.5
0.2888
0.5305
1.82
0.9716
2.91
Semi Deviation
N/A
1.05
N/A
N/A
1.34
N/A
N/A
6.04
2.64
2.05
Information Ratio
(0.05)
(0.06)
(0.11)
(0.15)
0.0121
(0.12)
(0.17)
0.0661
0.0781
0.0682
Value At Risk
(3.72)
(1.91)
(1.16)
(3.71)
(2.33)
(3.21)
(1.32)
(5.16)
(5.17)
(4.47)
Expected Short fall
N/A
(1.22)
N/A
N/A
(1.88)
N/A
N/A
(6.69)
(3.77)
(2.94)
Downside Deviation
N/A
1.12
N/A
N/A
1.45
N/A
N/A
7.17
2.89
2.58
Semi Variance
N/A
1.09
N/A
N/A
1.8
N/A
N/A
36.51
6.95
4.18

Meribank Biotech Competition Performance Charts

Five steps to successful analysis of Meribank Biotech Competition

Meribank Biotech's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Meribank Biotech in relation to its competition. Meribank Biotech's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Meribank Biotech in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Meribank Biotech's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Meribank Biotech, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Meribank Biotech position

In addition to having Meribank Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Airlines Thematic Idea Now

Airlines
Airlines Theme
Domestic and international airlines and airline services. The Airlines theme has 12 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Airlines Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Meribank Stock Analysis

When running Meribank Biotech's price analysis, check to measure Meribank Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Meribank Biotech is operating at the current time. Most of Meribank Biotech's value examination focuses on studying past and present price action to predict the probability of Meribank Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Meribank Biotech's price. Additionally, you may evaluate how the addition of Meribank Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY